DEVELOP A SAFE AND EFFECTIVE THERAPEUTIC TO MITIGATE SEVERE OUTCOMES, INCLUDING BUT NOT LIMITED TO MORTALITY, IN PATIENTS WITH SEVERE INFECTION OR SEPSIS OF ANY ETIOLOGY.
$749,000
| Recipient | BIOAEGIS THERAPEUTICS INC UEI G2AZAC2PG7X3 |
|---|---|
| Award ID | 75A50121C00060 |
| Award amount | $749,000 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 325413 — IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING |
| PSC | AN13 |
| Start date | Jun 11, 2021 |
| End date | Nov 30, 2022 |
| Place of performance | MORRISTOWN, NJ |
| Record updated | Aug 25, 2022 |
View the official award record
More awards won by BIOAEGIS THERAPEUTICS INC
BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I
Department of Health and Human Services · $20,000,000 · Sep 21, 2023
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids